Program
entecavir
Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.
Drug pageEntecavir: every studyMany companies study it; this page follows only the 32 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 240 open or running | phase 4since Aug 29, 2006 | May 4, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 40 open or running | phase 4since Jan 30, 2008 | Jan 30, 2008 | none ahead |
| Ascentage Pharma Group Internationalits history only | 11 open or running | phase 2since Sep 24, 2020 | Sep 24, 2020 | none ahead |
| Aucta Pharmaceuticalsits history only | 10 open or running | phase 1since Jul 27, 2017 | Jul 27, 2017 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 4since Jul 26, 2015 | Jul 26, 2015 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | no phasesince Jan 22, 2019 | Jan 22, 2019 | none ahead |
Also a collaborator on its studies: ICON Clinical Research and CPR Pharma Services Pty Ltd, Australia.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hanmi Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2015First study: phase 4 study in Hepatitis B, ChronicFirst studyNCT02523547 · 134 enrolled · Korea, Republic of
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
The one study Hanmi Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02523547Hepatitis B, Chronic · Korea, Republic of | 4 | UNKNOWN | Feb 2017 | 134 |
How it is read
Names in the registry
- “Entecavir”, 28 entries
- “entecavir”, 4 entries
- “Entecavir (ETV)”, 2 entries
- “Entecavir + Tenofovir”, 2 entries
- “P1101 + Nivolumab + Entecavir”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 34 studies
- Hepatitis B, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.